托帕利单抗治疗鼻咽癌的疗效和安全性：一项荟萃分析

IF 2.3 4区医学 Q3 ONCOLOGY

Current Problems in Cancer Pub Date : 2025-07-31 DOI:10.1016/j.currproblcancer.2025.101238

Yiwei Sun , Lingqin Kong

{"title":"托帕利单抗治疗鼻咽癌的疗效和安全性：一项荟萃分析","authors":"Yiwei Sun , Lingqin Kong","doi":"10.1016/j.currproblcancer.2025.101238","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To systematically assess the effectiveness and safety of toripalimab in the treatment of nasopharyngeal carcinoma (NPC) based on clinical trial reports.</div></div><div><h3>Methods</h3><div>Four databases (PubMed, Web of Science, Embase, and The Cochrane Library) were comprehensively searched to collect randomized controlled trials (RCTs) or single-arm clinical trials of toripalimab in treating NPC up to May 8, 2025. Two investigators independently screened relevant studies according to the inclusion/exclusion criteria. Data analyses were performed using R4.0 software.</div></div><div><h3>Results</h3><div>This analysis included 9 trials, including 7 single-arm trials and 2 RCTs, involving a total of 608 patients. The meta-analysis results indicated that toripalimab could improve objective response rate (RR=0.780, 95 % CI: 0.554-0.911) and disease control rate (RR = 0.921, 95 % CI: 0.788-0.992) in NPC patients. Nonetheless, toripalimab administration could also induce adverse reactions. The incidence of the following adverse reactions was relatively high, at 60.6 % for anemia, 65.4 % for nausea, and 46.1 % for leukopenia.</div></div><div><h3>Conclusion</h3><div>Toripalimab administration can significantly improve the objective response rate and disease control rate in NPC patients. Meanwhile, specific clinical measures shall be taken to prevent and manage the adverse reactions induced by this medication.</div></div>","PeriodicalId":55193,"journal":{"name":"Current Problems in Cancer","volume":"58 ","pages":"Article 101238"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of toripalimab in treating nasopharyngeal carcinoma: A meta-analysis\",\"authors\":\"Yiwei Sun , Lingqin Kong\",\"doi\":\"10.1016/j.currproblcancer.2025.101238\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To systematically assess the effectiveness and safety of toripalimab in the treatment of nasopharyngeal carcinoma (NPC) based on clinical trial reports.</div></div><div><h3>Methods</h3><div>Four databases (PubMed, Web of Science, Embase, and The Cochrane Library) were comprehensively searched to collect randomized controlled trials (RCTs) or single-arm clinical trials of toripalimab in treating NPC up to May 8, 2025. Two investigators independently screened relevant studies according to the inclusion/exclusion criteria. Data analyses were performed using R4.0 software.</div></div><div><h3>Results</h3><div>This analysis included 9 trials, including 7 single-arm trials and 2 RCTs, involving a total of 608 patients. The meta-analysis results indicated that toripalimab could improve objective response rate (RR=0.780, 95 % CI: 0.554-0.911) and disease control rate (RR = 0.921, 95 % CI: 0.788-0.992) in NPC patients. Nonetheless, toripalimab administration could also induce adverse reactions. The incidence of the following adverse reactions was relatively high, at 60.6 % for anemia, 65.4 % for nausea, and 46.1 % for leukopenia.</div></div><div><h3>Conclusion</h3><div>Toripalimab administration can significantly improve the objective response rate and disease control rate in NPC patients. Meanwhile, specific clinical measures shall be taken to prevent and manage the adverse reactions induced by this medication.</div></div>\",\"PeriodicalId\":55193,\"journal\":{\"name\":\"Current Problems in Cancer\",\"volume\":\"58 \",\"pages\":\"Article 101238\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Problems in Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0147027225000650\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Problems in Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147027225000650","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的根据临床试验报告，系统评价托帕利单抗治疗鼻咽癌的有效性和安全性。方法综合检索PubMed、Web of Science、Embase、The Cochrane Library 4个数据库，收集截至2025年5月8日的托帕利单抗治疗鼻咽癌的随机对照试验（RCTs）或单臂临床试验。两名研究者根据纳入/排除标准独立筛选相关研究。采用R4.0软件进行数据分析。结果本分析纳入9项试验，包括7项单臂试验和2项随机对照试验，共涉及608例患者。meta分析结果显示，托帕利单抗可提高鼻咽癌患者的客观有效率（RR=0.780, 95% CI: 0.554-0.911）和疾病控制率（RR= 0.921, 95% CI: 0.788-0.992）。然而，托帕利单抗也可能引起不良反应。以下不良反应的发生率相对较高，贫血为60.6%，恶心为65.4%，白细胞减少为46.1%。结论托利帕单抗可显著提高鼻咽癌患者的客观有效率和疾病控制率。同时，应采取针对性的临床措施，预防和管理本品引起的不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of toripalimab in treating nasopharyngeal carcinoma: A meta-analysis

Purpose

To systematically assess the effectiveness and safety of toripalimab in the treatment of nasopharyngeal carcinoma (NPC) based on clinical trial reports.

Methods

Four databases (PubMed, Web of Science, Embase, and The Cochrane Library) were comprehensively searched to collect randomized controlled trials (RCTs) or single-arm clinical trials of toripalimab in treating NPC up to May 8, 2025. Two investigators independently screened relevant studies according to the inclusion/exclusion criteria. Data analyses were performed using R4.0 software.

Results

This analysis included 9 trials, including 7 single-arm trials and 2 RCTs, involving a total of 608 patients. The meta-analysis results indicated that toripalimab could improve objective response rate (RR=0.780, 95 % CI: 0.554-0.911) and disease control rate (RR = 0.921, 95 % CI: 0.788-0.992) in NPC patients. Nonetheless, toripalimab administration could also induce adverse reactions. The incidence of the following adverse reactions was relatively high, at 60.6 % for anemia, 65.4 % for nausea, and 46.1 % for leukopenia.

Conclusion

Toripalimab administration can significantly improve the objective response rate and disease control rate in NPC patients. Meanwhile, specific clinical measures shall be taken to prevent and manage the adverse reactions induced by this medication.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Problems in Cancer 医学-肿瘤学

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

15 days

期刊介绍： Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal''s scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Papers that focus solely on laboratory-based or basic science research are discouraged. The journal''s format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.